Table 4.

Interaction between CD4 count and isoniazid preventive therapy use on mortality (n=2540)

	IPT use	#deaths/pys	Rate per 100 pys	Unadjusted HR (95% CI)	Adjusted HR2 (95% CI)
Baseline CD4
< 50	No	58/259	22.41	11	13
	Yes	8/82	9.70	0.44 (0.21 – 0.93)	0.68 (0.30 – 1.51)
50–100	No	50/324	15.42	1	1
	Yes	8/125	6.40	0.42 (0.20 – 0.89)	0.58 (0.26 – 1.28)
101 – 200	No	56/699	8.01	1	1
	Yes	11/359	3.07	0.39 (0.20 – 0.74)	0.48 (0.24 – 0.96)
>200	No	38/650	5.85	1	1
	Yes	4/268	1.49	0.26 (0.09 – 0.73)	0.33 (0.12 – 0.95)
Time period following ART initiation
<3 months	No	113/561	20.15	1	1
	Yes	15/226	6.65	0.33 (0.19 – 0.57)	0.50 (0.27 – 0.93)
>3 months	No	114/1487	7.67	1	1
	Yes	17/638	2.67	0.35 (0.21 – 0.58)	0.51 (0.29 – 0.91)

¹P-value for interaction=0.84;

²Adjusted for age group, baseline WHO stage, year started on ART and individual company (and CD4 baseline for time period);

³P-value for interaction=0.79 pys=person-years